Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ FDA approves image and data management/analysis platform
➤ Results from pivotal Phase 3 trial for new Demodex treatment
➤ Trial demonstrates safety, efficacy of mydriasis-reversal drug in pediatric patients
➤ Phase 3 pivotal trial for novel dry eye disease, MGD drug candidate
➤ Phase 3 results for investigational geographic atrophy therapy
➤ New coalition supports sustainability in ophthalmology
➤ ASCRS news and events
➤ Topline results from Phase 3 trials of presbyopia-mitigating drop ➤ Study: Long-term visual outcomes of at-home telemonitoring ➤ AAO IRIS Registry Report ➤ Innovations in capsulotomy technology ➤ Complimentary access to video journal ➤ ASCRS news and events
➤ FDA approves new phaco system
➤ Next-generation canaloplasty device launch
➤ New Nd:YAG laser launch
➤ Researchers explore non-surgical option to address vision loss
➤ Non-invasive method to examine conjunctival goblet cells in vivo
➤ ASCRS news and events
➤ Phase 3 clinical trials complete for ‘superpotent’ corticosteroid
➤ New rapid, quantitative MMP-9 tear test
➤ First pediatric patient dosed with experimental gene-editing therapy for Leber congenital amaurosis
➤ Study: Comparison of NCX 470 to latanoprost for glaucoma
➤ Collaborations for inherited retinal diseases
➤ ASCRS news and events
➤ Topline data from Phase 3 trial of presbyopia-correcting drop
➤ FDA gives 510(K) approval to updated neuromodulation therapy for increased tear production
➤ Enrollment complete for Phase 3 trial of reproxalap
➤ DME trial to focus on underrepresented patient populations
➤ BLA submitted to FDA for wet AMD therapy
➤ Companies collaborate to further develop gene therapy for retinal disease
➤ ASCRS news and events
➤ FDA approves new ICL
➤ Home tonometer receives 510(k) clearance
➤ First patient treated in what will be the largest standalone MIGS clinical trial
➤ Topline results from second Phase 3 trial of mydriasis-reversing drug
➤ ASCRS news and events
➤ Launch of Phase 3 clinical trial for presbyopia drop candidate
➤ Topline results for investigational dry eye therapy
➤ Positive findings for photobiomodulation dry AMD treatment
➤ Enrollment completed for investigational oral diabetic retinopathy therapy
➤ Longer-term data from Phase 3 studies evaluating geographic atrophy therapy released
➤ Orphan drug designation granted to investigational retinitis pigmentosa treatment
➤ ASCRS news and events
➤ Results from pivotal amblyopia trial
➤ Phase 2 clinical program for third-generation keratoconus treatment
➤ Study compares tolerability of standard drop vs. novel drug delivery device
➤ Phase 3 clinical studies for investigational presbyopia drop complete
➤ Orphan drug designation granted for fungal keratitis treatment
➤ Full rights regained for investigational dry AMD therapy
➤ ASCRS news and events
➤ Launch of IOL made with new ‘glistening-free’ material
➤ Enrollment complete in study of mydriasis-reversing drop in a pediatric group
➤ Acquisition of electrophysiology medical device company
➤ Licensing of investigational neuroprotective drug
➤ ASCRS news and events
➤ FDA approves first drug-eluting contact lens
➤ FDA accepts 510(k) submission for new femto-phaco device
➤ Phase 2 study begins to evaluate an immunomodulatory agent for dry eye
➤ Licensing agreement for optic nerve-protective therapy
➤ Phase 3 study to evaluate protein replacement solution for dry eye
➤ Study: Impact of age on SMILE outcomes
➤ ASCRS news and events
